Addex Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Addex Therapeutics (ADXN).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$30Upside to Avg. PT+852.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$30
Aug 28, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$30
Jul 31, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Upgrade	Neutral→Buy	$30

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Addex Therapeutics (NASDAQ:ADXN) with a Buy and maintains $30 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Addex Therapeutics (NASDAQ:ADXN) with a Buy and maintains $30 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Addex Therapeutics to Buy, Announces $30 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Addex Therapeutics (NASDAQ:ADXN) from Neutral to Buy and announces $30 price target.

Benzinga Newsdesk

Why Did HC Wainwright Downgrade Addex Therapeutics

Vandana Singh

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

Upgrades

Benzinga Insights

PRO
HC Wainwright & Co. Downgrades Addex Therapeutics to Neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Addex Therapeutics (NASDAQ:ADXN) from Buy to Neutral.

Benzinga Newsdesk

Addex Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Addex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PRO
HC Wainwright & Co. Upgrades Addex Therapeutics to Buy, Announces $30 Price Target

Why Did HC Wainwright Downgrade Addex Therapeutics

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

PRO
HC Wainwright & Co. Downgrades Addex Therapeutics to Neutral

People Also Watch

People Also Watch

Addex Therapeutics Ltd

ニュース

パートナーシップ

ベンジンガ・グローバル

Addex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PROHC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PROHC Wainwright & Co. Upgrades Addex Therapeutics to Buy, Announces $30 Price Target

Why Did HC Wainwright Downgrade Addex Therapeutics

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022

PROHC Wainwright & Co. Downgrades Addex Therapeutics to Neutral

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Addex Therapeutics, Maintains $30 Price Target

PRO
HC Wainwright & Co. Upgrades Addex Therapeutics to Buy, Announces $30 Price Target

PRO
HC Wainwright & Co. Downgrades Addex Therapeutics to Neutral